Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Pfizer reports novel GHR antagonist antibodies

July 19, 2013

Novel plasmid-encoded treatment for patients with type 1 diabetes

July 19, 2013

Alexion commences phase I trial of treatment candidate for MoCD

July 18, 2013

A novel adeno-associated virus gene therapy for mucopolysaccharidosis IIIA

July 17, 2013

Alize Pharma begins first phase I trial of unacylated ghrelin analogue

July 16, 2013

Zealand Pharma and Boehringer Ingelheim design new GLP-1 and GL receptor agonists

July 16, 2013

Lilly reports promising result for LY-2409021 in patients with type 1 and 2 diabetes

July 15, 2013

Biodel completes dosing in phase II trial of ultra-rapid-acting injectable mealtime insulin BIOD-123

July 12, 2013

Ultragenyx obtains worldwide license for triheptanoin

July 12, 2013

Researchers describe unique properties of diabetes treatment candidate SKL-18287

July 12, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...